Wren Therapeutics has developed oral small molecules that suppress the production of toxic alpha-synuclein protein forms in cellular and mouse models used to study Parkinson’s disease. The potential first-in-class molecules were designed with Wren’s technology platform to hinder processes involved in the generation of alpha-synuclein oligomers, the…
Exposure to high concentrations of copper accelerates the formation of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease, a study shows. The study, “Single-Particle Resolution of Copper-Associated Annular α‑Synuclein Oligomers Reveals Potential Therapeutic Targets of Neurodegeneration,” was published in the journal…
In Parkinson’s patients, greater nerve damage in the skin around the ankle is significantly associated with subsequent progression of motor symptoms, while the presence of such damage in neck skin is linked to progressive cognitive decline, a study shows. Notably, this nerve damage progression was not related to increased…
ABBV-0805, AbbVie’s experimental antibody-based therapy for Parkinson’s disease, selectively binds to toxic clumps of the alpha-synuclein protein — a hallmark of the disease — preventing their spread and prolonging survival in mouse models of Parkinson’s, a study shows. Also, the investigational antibody was found to bind to harmful…
LL-37, a natural antimicrobial molecule present in the brain and gut, selectively binds to harmful clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease — and prevents their further aggregation and toxic effects in lab-grown nerve cells, a study shows. The discovery of such a strong suppressor…
Get regular updates to your inbox.
